CNS 2021 poster: Eladocagene exuparvovec improves body weight and reduces respiratory infections in patients with aromatic L-amino acid decarboxylase (AADC) deficiency
Changes in body weight and rate of respiratory infections in children with AADC deficiency following treatment with eladocagene exuparvovec, an investigational gene therapy, are presented in this poster from the 2021 CNS Annual Meeting
The role of intraputaminal infusion of eladocagene exuparvovec as a gene therapy for treating the symptoms of AADC deficiency in children is presented
The efficacy of eladocagene exuparvovec in increasing body weight (a positive indicator of AADC deficiency) is investigated in a small group of children across 3 single-center trials
The effects of eladocagene exuparvovec on minimizing respiratory infections and pneumonia were also assessed in this patient population
Treatment emergent adverse events with eladocagene exuparvovec are also described
Eladocagene exuparvovec is an investigational gene therapy product currently being developed by PTC Therapeutics for the treatment of patients with deficiency of a protein calledAADC.Eladocageneexuparvovec does not currently have a marketing authorization for the treatment of AADC deficiency.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-AADC-2100520 I February 2022
Sign in or register to access exclusive content on this site
Some cookies are essential, others help us improve your experience by providing insights into how the website is used. Select one or more of the cookie types listed below, and then save your preferences. Refer to our Cookies Statement for more information.
Performance cookies, which help us measure the website’s performance and improve your experience. In using performance cookies we do not store any personal data, and only use the information collected through these cookies in aggregated and anonymised form.